Skip to main content

Table 1 Mean basline (BL), week 48, and changes from BL in lipid parameters.

From: Metabolic evaluation of Study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1 infected subjects

 

Overall (N = 568 to 575)

QD (N = 290 to 295)

BID (N = 276 to 280)

TC (mmol/L) BL, Wk48, Δ

4.00, 4.82, +0.82

4.02, 4.77, +0.75

3.97, 4.87, +0.89

TG (mmol/L) BL, Wk48, Δ

1.74, 2.35, +0.61

1.71, 2.22, +0.51

1.76, 2.48, +0.72

LDL (mmol/L) BL, Wk48, Δ

2.50, 2.69, +0.19

2.53, 2.67, +0.14

2.47, 2.71, +0.24

HDL (mmol/L) BL, Wk48, Δ

1.02, 1.21, +0.19

1.03, 1.22, +0.19

1.01, 1.20, +0.19

TC:HDL ratio BL Wk48, Δ

4.40, 4.21, -0.20

4.46, 4.11, -0.35

4.34, 4.31, -0.03

LDL:HDL ratio BL, Wk48, Δ

2.69, 2.34, -0.35

2.74, 2.31, -0.43

2.64, 2.38, -0.27

10-yr CHD risk (LDL) (%) BL, Wk48, Δ

4.63, 4.60, -0.04

4.49, 4.43, -0.06

4.77, 4.76, -0.01

10-yr CHD risk (TC) (%) BL, Wk48, Δ

4.25, 5.02, +0.78

4.29, 4.89, +0.60

4.21, 5.17, +0.96